ClinicalTrials.gg
CompletedNCT00708097Updated Jan 1, 2015Results posted

In Situ Caries Efficacy of Fluoride Toothpastes

A Phase 3 interventional study of NaF and Placebo in Caries, sponsored by GlaxoSmithKline. Completed at 1 site in United States. Open to participants aged 18 Years to 78 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-01-01.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
57
Allocation
Randomized
Ages
18 Years to 78 Years
Sex
All
01

Study summary

This study is to evaluate the effect of fluoride dentifrices on enamel with artificial caries lesions in an in situ model

Read the detailed description

In situ models represent an acceptable approach for testing the anti-caries potential of fluoride products. This study is to evaluate the effect of fluoride dentifrice containing 1450 parts per million fluoride (ppm F) on enamel with artificial caries lesions in an in situ model. The study toothpaste containing sodium fluoride (NaF) and 0.4% carbopol will be compared to 4 other dentifrices. Comparator toothpastes include NaF toothpaste (1400 ppm F), NaF toothpaste (675 ppm F), sodium monofluorophosphate (NaMFP) and NaF toothpaste (1450 ppm F) and placebo toothpaste (0 ppm F).

02

Conditions studied

  • Caries

Keywords

  • fluoride
  • in situ
  • remineralization
  • enamel
  • caries
03

In context

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 78 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consent:Demonstrates understanding of the study and willingness to participate as evidenced by voluntary written and has received a signed and dated copy of the informed consent form.
  • Age:Aged between 18 and 80 years.
  • Compliance:Understands and is willing, able and likely to comply with all study procedures and restrictions.
  • General Health:Good general health with (in the opinion of the investigator) no and relevant abnormalities of medical history or physical examination.
  • Fluoride:Currently living in the Indianapolis, Indiana area and not taking fluoride supplements for medical reasons
  • Dentures: a)Currently wearing a removable mandibular partial denture with sufficient room in both posterior buccal flange areas to accommodate two enamel specimens on each side, four specimens in total - required dimensions 12 x 7 millimeter (mm) per side. b) Willing to have their denture modified to accommodate enamel test specimens and willing and capable of wearing their removable mandibular partial dentures 24 hours per day during the experimental periods
  • Dental health: Have no current active caries or periodontal disease that may compromise the study or the health of the subjects and all restorations in a good state of repair
  • Salivary flow:Have a salivary flow rate in the range of normal values (unstimulated whole saliva flow rate = 0.2 milliliter (mL)/minute; gum base stimulated whole saliva flow rate = 0.8 mL/minute)

Exclusion criteria

Exclusion Criteria:

  • Pregnancy: Women who are known to be pregnant or who are intending to become pregnant over the duration of the study.
  • Breast-feeding:Women who are breast-feeding.
  • Allergy/Intolerance: Known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients.
  • Antibiotics: Currently taking antibiotics or have taken antibiotics in the two weeks prior to the screening visit
  • Clinical Study/Experimental Medication: a) Participation in another clinical study or receipt of an drug within 30 days of the screening visit.b) Participation in another GSKCH investigational dental product study within 7 days of first study treatment c)Previous participation in this study.
  • Substance abuse: Recent history (within the last year) of alcohol or other substance abuse.
  • Personnel:a) A member of the site study staff living in same household.b)An employee of the sponsor. c) Any employee of any toothpaste manufacturer or their spouse or family member
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Investigator)
Enrollment
57 participants (actual)

Study arms

  • Experimental
    NaF toothpaste(1450 ppmF)

    Study toothpaste containing 1450 ppm F as NaF and 0.4% carbopol as excipient.

    Drug: NaF

  • Active comparator
    NaF toothpaste (1400 ppmF)

    Study toothpaste containing 1400 ppm F as NaF

    Drug: NaF

  • Active comparator
    NaMFP/NaF toothpaste (1450 ppmF)

    Reference toothpaste containing 1000 ppm F as NaMFP and 450 ppm F as NaF

    Drug: NaF · Drug: NaMFP

  • Active comparator
    NaF toothpaste (675 ppmF)

    Study toothpaste containing 675 ppm F as NaF

    Drug: NaF

  • Placebo comparator
    Placebo toothpaste (0 ppmF)

    Fluoride free placebo toothpaste (0 ppm F)

    Drug: Placebo

Interventions

  • DrugNaF

    Fluoride

    Also known as: Fluoride

  • DrugPlacebo

    Placebo

  • DrugNaMFP

    Fluoride

06

What researchers measure

Primary outcomes

  1. Percentage Surface Microhardness Recovery (%SMHR) of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF) and NaF Toothpaste (1400ppmF)

    SMH test was used to assess mineral status of partially demineralized enamel specimens using Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening/demineralization while decrease in the indentation represents rehardening/ remineralization of enamel surface. Percent SMHR was calculated from indentation values of enamel specimens at baseline(B); after intra-oral exposure(R) on Day 14; and after in-vitro demineralization(D) on Day 14 using formula \[(D-R)/(D-B)\]\*100.

    Time frame: Baseline to 14 days

Secondary outcomes

  1. Percentage SMHR of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaMFP/NaF Toothpaste (1450ppmF), NaF Toothpaste (675ppmF) and Placebo Toothpaste (0ppmF)

    SMH test was used to assess mineral status of partially demineralized enamel specimens using Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening/demineralization while decrease in the indentation represents rehardening/ remineralization of enamel surface. Percent SMHR was calculated from indentation values of enamel specimens at baseline(B); after intra-oral exposure(R) on Day 14; and after in-vitro demineralization(D) on Day 14 using formula \[(D-R)/(D-B)\]\*100.

    Time frame: Baseline to 14 days

  2. Percentage SMHR of Demineralized Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste(1450ppmF) and Placebo Toothpaste (0ppmF)

    SMH test was used to assess mineral status of partially demineralized enamel specimens using Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening/demineralization while decrease in the indentation represents rehardening/ remineralization of enamel surface. Percent SMHR was calculated from indentation values of enamel specimens at baseline(B); after intra-oral exposure(R) on Day 14; and after in-vitro demineralization(D) on Day 14 using formula \[(D-R)/(D-B)\]\*100.

    Time frame: Baseline to 14 days

  3. Enamel Fluoride Uptake (Sound Enamel Specimens)

    Enamel fluoride uptake was determined using the microdrill enamel biopsy technique. The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores. The difference between treatments was calculated with respect to fluoride uptake by enamel.

    Time frame: Baseline to 14 days

  4. Enamel Fluoride Uptake (Demineralized Specimens)

    Enamel fluoride uptake was determined using the microdrill enamel biopsy technique. The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores. The difference between treatments was calculated with respect to fluoride uptake by enamel.

    Time frame: Baseline to 14 days

07

Results

Posted Jun 24, 2013

Participant flow

Period 1
Participant flow — Period 1
MilestoneSodium Fluoride (NaF) Toothpaste(1450 Parts Per Million(Ppm)F)NaF Toothpaste (1400ppmF)Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Started1112121111
Completed111112910
Not completed01021
Withdrew: Protocol violation01020
Withdrew: Other reason00001
Period 2
Participant flow — Period 2
MilestoneSodium Fluoride (NaF) Toothpaste(1450 Parts Per Million(Ppm)F)NaF Toothpaste (1400ppmF)Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Started1012101110
Completed101191010
Not completed01110
Withdrew: Protocol violation01110
Period 3
Participant flow — Period 3
MilestoneSodium Fluoride (NaF) Toothpaste(1450 Parts Per Million(Ppm)F)NaF Toothpaste (1400ppmF)Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Started911101010
Completed911101010
Not completed00000
Period 4
Participant flow — Period 4
MilestoneSodium Fluoride (NaF) Toothpaste(1450 Parts Per Million(Ppm)F)NaF Toothpaste (1400ppmF)Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Started12910118
Completed12910118
Not completed00000
Period 5
Participant flow — Period 5
MilestoneSodium Fluoride (NaF) Toothpaste(1450 Parts Per Million(Ppm)F)NaF Toothpaste (1400ppmF)Sodium Monofluorophosphate (NaMFP)/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Started89111012
Completed89111012
Not completed00000

Outcome measures

PrimaryPercentage Surface Microhardness Recovery (%SMHR) of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF) and NaF Toothpaste (1400ppmF)

SMH test was used to assess mineral status of partially demineralized enamel specimens using Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening/demineralization while decrease in the indentation represents rehardening/ remineralization of enamel surface. Percent SMHR was calculated from indentation values of enamel specimens at baseline(B); after intra-oral exposure(R) on Day 14; and after in-vitro demineralization(D) on Day 14 using formula \[(D-R)/(D-B)\]\*100.

Time frame:
Baseline to 14 days
Reported as:
Least squares mean · Percentage SMHR
Percentage Surface Microhardness Recovery (%SMHR) of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF) and NaF Toothpaste (1400ppmF)
Percentage SMHRNaF Toothpaste (1450ppmF)NaF Toothpaste (1400ppmF)
Percentage Surface Microhardness Recovery (%SMHR) of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF) and NaF Toothpaste (1400ppmF)28.31 ± 5.5426.32 ± 5.51
Statistical analysis
  • NaF Toothpaste (1450ppmF) vs NaF Toothpaste (1400ppmF) · ANOVA · p = 0.5757 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 1.98 · 95% CI -5.00 to 8.97Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
SecondaryPercentage SMHR of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaMFP/NaF Toothpaste (1450ppmF), NaF Toothpaste (675ppmF) and Placebo Toothpaste (0ppmF)

SMH test was used to assess mineral status of partially demineralized enamel specimens using Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening/demineralization while decrease in the indentation represents rehardening/ remineralization of enamel surface. Percent SMHR was calculated from indentation values of enamel specimens at baseline(B); after intra-oral exposure(R) on Day 14; and after in-vitro demineralization(D) on Day 14 using formula \[(D-R)/(D-B)\]\*100.

Time frame:
Baseline to 14 days
Reported as:
Least squares mean · Percentage SMHR
Percentage SMHR of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaMFP/NaF Toothpaste (1450ppmF), NaF Toothpaste (675ppmF) and Placebo Toothpaste (0ppmF)
Percentage SMHRNaF/Carbopol Toothpaste(1450ppmF)NaF Toothpaste(1400ppmF)NaMFP/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Percentage SMHR of Sound Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaMFP/NaF Toothpaste (1450ppmF), NaF Toothpaste (675ppmF) and Placebo Toothpaste (0ppmF)28.31 ± 5.5426.32 ± 5.5126.13 ± 5.4925.52 ± 5.4853.38 ± 5.52
Statistical analysis
  • NaF/Carbopol Toothpaste(1450ppmF) vs NaMFP/NaF Toothpaste (1450ppmF) · ANOVA · p = 0.5387 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 2.17 · 95% CI -4.79 to 9.14Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaF/Carbopol Toothpaste(1450ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = 0.4306 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 2.79 · 95% CI -4.18 to 9.77Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaF/Carbopol Toothpaste(1450ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: -25.07 · 95% CI -32.09 to -18.06Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaF Toothpaste(1400ppmF) vs NaMFP/NaF Toothpaste (1450ppmF) · ANOVA · p = 0.9567 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 0.19 · 95% CI -6.71 to 7.09Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaF Toothpaste(1400ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = 0.8188 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 0.81 · 95% CI -6.14 to 7.76Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaF Toothpaste(1400ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: -27.06 · 95% CI -34.03 to -20.08Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaMFP/NaF Toothpaste (1450ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = 0.8599 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 0.62 · 95% CI -6.28 to 7.51Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaMFP/NaF Toothpaste (1450ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: -27.25 · 95% CI -34.20 to -20.30Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaF Toothpaste (675ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: -27.87 · 95% CI -34.84 to -20.89Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
SecondaryPercentage SMHR of Demineralized Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste(1450ppmF) and Placebo Toothpaste (0ppmF)

SMH test was used to assess mineral status of partially demineralized enamel specimens using Wilson 2100 Hardness tester. SMH was determined by measuring the length of the indentations of enamel specimens. An increase in the indentation length compared to the baseline indicates softening/demineralization while decrease in the indentation represents rehardening/ remineralization of enamel surface. Percent SMHR was calculated from indentation values of enamel specimens at baseline(B); after intra-oral exposure(R) on Day 14; and after in-vitro demineralization(D) on Day 14 using formula \[(D-R)/(D-B)\]\*100.

Time frame:
Baseline to 14 days
Reported as:
Least squares mean · Percentage SMHR
Percentage SMHR of Demineralized Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste(1450ppmF) and Placebo Toothpaste (0ppmF)
Percentage SMHRNaF Toothpaste(1450ppmF)NaF Toothpaste(1400ppmF)NaMFP/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Percentage SMHR of Demineralized Enamel Specimens Exposed to NaF Toothpaste (1450ppmF), NaF Toothpaste (1400ppmF), NaF Toothpaste (675ppmF), NaMFP/NaF Toothpaste(1450ppmF) and Placebo Toothpaste (0ppmF)34.62 ± 2.8236.06 ± 2.7931.12 ± 2.7727.15 ± 2.7711.10 ± 2.80
Statistical analysis
  • NaF Toothpaste(1450ppmF) vs NaF Toothpaste(1400ppmF) · ANOVA · p = 0.5451 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: -1.45 · 95% CI -6.15 to 3.26Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaF Toothpaste(1450ppmF) vs NaMFP/NaF Toothpaste (1450ppmF) · ANOVA · p = 0.1433 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 3.50 · 95% CI -1.20 to 8.19Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaF Toothpaste(1450ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = 0.0020 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 7.47 · 95% CI 2.78 to 12.16Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaF Toothpaste(1450ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 23.52 · 95% CI 18.79 to 28.25Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaF Toothpaste(1400ppmF) vs NaMFP/NaF Toothpaste (1450ppmF) · ANOVA · p = 0.0373 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 4.94 · 95% CI 0.29 to 9.59Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaF Toothpaste(1400ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = 0.0002 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 8.92 · 95% CI 4.24 to 13.59Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaF Toothpaste(1400ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 24.97 · 95% CI 20.27 to 29.66Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaMFP/NaF Toothpaste (1450ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = 0.0925 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 3.98 · 95% CI -0.66 to 8.61Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaMFP/NaF Toothpaste (1450ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 20.03 · 95% CI 15.35 to 24.70Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
  • NaF Toothpaste (675ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 16.05 · 95% CI 11.36 to 20.74Difference is first named treatment minus second named treatment such that a negative difference favors the first named treatment.
SecondaryEnamel Fluoride Uptake (Sound Enamel Specimens)

Enamel fluoride uptake was determined using the microdrill enamel biopsy technique. The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores. The difference between treatments was calculated with respect to fluoride uptake by enamel.

Time frame:
Baseline to 14 days
Reported as:
Least squares mean · micrograms (μg)*F/centimeters(cm)^2]
Enamel Fluoride Uptake (Sound Enamel Specimens)
micrograms (μg)*F/centimeters(cm)^2]NaF Toothpaste (1450ppmF)NaF Toothpaste (1400ppmF)NaMFP/ NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Enamel Fluoride Uptake (Sound Enamel Specimens)648.06 ± 47.10650.07 ± 46.30541.16 ± 45.91487.14 ± 45.86425.59 ± 46.67
Statistical analysis
  • NaF Toothpaste (1450ppmF) vs NaF Toothpaste (1400ppmF) · ANOVA · p = 0.9697 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: -2.01 · 95% CI -106.34 to 102.32Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaF Toothpaste (1450ppmF) vs NaMFP/ NaF Toothpaste (1450ppmF) · ANOVA · p = 0.0440 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 106.90 · 95% CI 2.92 to 210.87Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaF Toothpaste (1450ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = 0.0026 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 160.92 · 95% CI 56.96 to 264.88Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaF Toothpaste (1450ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 222.47 · 95% CI 117.58 to 327.36Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaF Toothpaste (1400ppmF) vs NaMFP/ NaF Toothpaste (1450ppmF) · ANOVA · p = 0.0382 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 108.91 · 95% CI 5.98 to 211.83Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaF Toothpaste (1400ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = 0.0021 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 162.93 · 95% CI 59.68 to 266.18Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaF Toothpaste (1400ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 224.48 · 95% CI 120.51 to 328.46Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaMFP/ NaF Toothpaste (1450ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = 0.3003 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 54.03 · 95% CI -48.56 to 156.61Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaF Toothpaste (675ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = 0.2432 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 61.55 · 95% CI -42.14 to 165.24Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaMFP/ NaF Toothpaste (1450ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = 0.0289 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 115.58 · 95% CI 12.02 to 219.13Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
SecondaryEnamel Fluoride Uptake (Demineralized Specimens)

Enamel fluoride uptake was determined using the microdrill enamel biopsy technique. The amount of fluoride uptake by enamel was calculated based on the amount of fluoride (F) divided by the area of the enamel cores. The difference between treatments was calculated with respect to fluoride uptake by enamel.

Time frame:
Baseline to 14 days
Reported as:
Least squares mean · μg*F/cm^2
Enamel Fluoride Uptake (Demineralized Specimens)
μg*F/cm^2NaF Toothpaste(1450ppmF)NaF Toothpaste (1400ppmF)NaMFP/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)
Enamel Fluoride Uptake (Demineralized Specimens)2499.47 ± 133.462513.37 ± 131.091923.76 ± 129.911861.80 ± 129.78686.18 ± 132.20
Statistical analysis
  • NaF Toothpaste(1450ppmF) vs NaF Toothpaste (1400ppmF) · ANOVA · p = 0.9293 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: -13.90 · 95% CI -322.47 to 294.66Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaF Toothpaste(1450ppmF) vs NaMFP/NaF Toothpaste (1450ppmF) · ANOVA · p = 0.0003 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 575.71 · 95% CI 268.24 to 883.17Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaF Toothpaste(1450ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 637.67 · 95% CI 330.30 to 945.03Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaF Toothpaste(1450ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 1813.29 · 95% CI 1503.03 to 2123.54Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaF Toothpaste (1400ppmF) vs NaMFP/NaF Toothpaste (1450ppmF) · ANOVA · p = 0.0002 · Adjusted mean difference: 589.61 · 95% CI 285.31 to 893.92Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaF Toothpaste (1400ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 651.57 · 95% CI 346.44 to 956.70Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaF Toothpaste (1400ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 1827.19 · 95% CI 1519.78 to 2134.60Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaMFP/NaF Toothpaste (1450ppmF) vs NaF Toothpaste (675ppmF) · ANOVA · p = 0.6874 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 61.96 · 95% CI -241.25 to 365.17Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaMFP/NaF Toothpaste (1450ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 · Adjusted mean difference: 1237.58 · 95% CI 931.46 to 1543.70Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.
  • NaF Toothpaste (675ppmF) vs Placebo Toothpaste (0ppmF) · ANOVA · p = <0.0001 (No adjustment made for multiple comparisons as the primary comparison was pre-specified.) · Adjusted mean difference: 1175.62 · 95% CI 869.15 to 1482.10Difference is first named treatment minus second named treatment such that a positive difference favors the first named treatment.

Adverse events

Collected over All AEs encountered or spontaneously reported following administration of any investigational product (including washout product), or for up to 5 days after the last administration of investigational product were recorded.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
NaF Toothpaste(1450ppmF)—0/50 (0%)3/50 (6%)
NaF Toothpaste (1400ppmF)—0/52 (0%)1/52 (1.9%)
NaMFP/NaF Toothpaste (1450ppmF)—0/53 (0%)3/53 (5.7%)
NaF Toothpaste (675ppmF)—0/53 (0%)4/53 (7.5%)
Placebo Toothpaste (0ppmF)—0/51 (0%)1/51 (2%)
Overall—0/57 (0%)10/57 (17.5%)
Most frequent other events
Most frequent other events
EventNaF Toothpaste(1450ppmF)NaF Toothpaste (1400ppmF)NaMFP/NaF Toothpaste (1450ppmF)NaF Toothpaste (675ppmF)Placebo Toothpaste (0ppmF)Overall
Gingival erythemaGastrointestinal disorders3/501/523/534/531/5110/57

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Randomized Participants
Mean65.5 ± 10.32
Sex: Female, Male
Sex: Female, Male(Participants)All Randomized Participants
Female34
Male23
Region of Enrollment
Region of Enrollment(participants)All Randomized Participants
United States57
08

Study locations

1 site
  • Indiana University School of Dentistry
    Indianapolis, Indiana 46202, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2008, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 4 years 11 months after primary completion. A results delay was requested in Sep 2011.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 1, 2008
First posted
Jul 2, 2008
Start
Apr 2008
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results delay requested
Sep 15, 2011
Results first posted
Jun 24, 2013
Last update
Jan 1, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 1, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00708097
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 2, 2008
Start date
Apr 2008
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Jun 24, 2013
Last update
Jan 1, 2015

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sodium Fluoride

Start the discussion